Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A quality evaluation strategy for multi-sourced active pharmaceutical ingredient (API) starting materials.

Peter F Gavin1, Bernard A Olsen, David D Wirth

  • 1Analytical Sciences Research & Development, Eli Lilly & Company, Lilly Research Laboratories, Indianapolis, IN 46285, USA. gavin.peter_f@lilly.com

Journal of Pharmaceutical and Biomedical Analysis
|April 20, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Formation of copper(I) from trace levels of copper(II) as an artifactual impurity in the HPLC analysis of olanzapine.

Journal of pharmaceutical and biomedical analysis·2016
Same author

A new statistical method for the automated detection of peaks in UV-DAD chromatograms of a sample mixture.

Talanta·2009
Same author

A simple and efficient approach to reversed-phase HPLC method screening.

Journal of pharmaceutical and biomedical analysis·2009
Same author

A quality by design approach to impurity method development for atomoxetine hydrochloride (LY139603).

Journal of pharmaceutical and biomedical analysis·2007
Same author

Is HPLC assay for drug substance a useful quality control attribute?

Journal of pharmaceutical and biomedical analysis·2007
Same author

Strategies for the investigation and control of process-related impurities in drug substances.

Advanced drug delivery reviews·2006

Establishing impurity specifications for active pharmaceutical ingredient (API) starting materials is crucial for drug commercialization. This study outlines a quality evaluation strategy using Phenyl methyl amino propanol (PMAP) to ensure API purity.

Area of Science:

  • Pharmaceutical Chemistry
  • Analytical Chemistry
  • Drug Development

Background:

  • Setting impurity specifications for Active Pharmaceutical Ingredient (API) starting materials is vital for drug commercialization and registration.
  • Understanding diverse manufacturing sources, routes, and the API process's tolerance for starting material impurities is essential.

Purpose of the Study:

  • To describe a strategy for purity method development and use test evaluation of starting materials.
  • To illustrate this strategy using Phenyl methyl amino propanol (PMAP), a key starting material for fluoxetine and atomoxetine hydrochloride.

Main Methods:

  • Utilized knowledge of actual and potential synthetic routes to predict impurities.
  • Guided purity method development based on predicted impurities.

Related Experiment Videos

  • Investigated multiple semi-orthogonal analytical methods (ion-pairing, ion interaction, hydrophilic interaction chromatography) and use tests.

    • Main Results:

    • A comprehensive strategy for evaluating starting material quality was developed and illustrated.
    • The approach successfully guided the selection and development of analytical methods for impurity profiling.
    • Semi-orthogonal chromatographic methods and use tests were found effective for quality assessment.

    Conclusions:

    • The described strategy provides a robust framework for establishing appropriate impurity specifications for API starting materials.
    • Understanding synthetic pathways and employing diverse analytical techniques are key to ensuring API quality and safety.
    • This quality evaluation approach supports the successful commercialization and registration of APIs.